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to enter the market and boost competition in the sector. However, manufacturers 
will have to ensure that biosimilars are sensibly price and also put proper sales 
and marketing support behind the product to address the low awareness amongst 
physicians and local payers.
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CoSt-Sharing and USe of BiologiC theraPieS in MediCare PatientS 
With rheUMatoid arthritiS
Doshi J.A.1, Li P.1, Hu T.1, Subedi P.2, Davis-Cerone M.2
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Objectives: Biologics represent major advances in the treatment of rheumatoid 
arthritis (RA) with eight agents available on the market by 2010. In the Medicare 
program, 3 agents are Part B covered infusibles, while the remaining five are Part D 
covered self-injectables. This study examines the association between cost sharing 
and the initiation and choice of RA biologic (Part D vs. Part B) in Medicare benefi-
ciaries. MethOds: Fee-for-service beneficiaries with continuous Part D coverage 
and RA (ICD-9-CM 714.xx) in the 2010 Medicare 5% files (N= 12,923) were examined. 
Dependent variables included initiation of any biologic among all RA patients and 
the use of a Part D (vs. Part B) biologic among biologic users. To isolate the effect of 
the specialty tier cost-sharing (from that of the donut hole) we further identified 
whether a Part D biologic was first initiated in the initial coverage limit (ICL) phase 
or not. The key independent variable was the beneficiary’s low income subsidy 
(LIS) status i.e. non-LIS vs. full-LIS as a proxy for higher (initially 25% to 35% coin-
surance followed by donut hole) vs. lower cost-sharing ($3-$5 copay), respectively. 
Multivariate logistic regressions with robust clustered standard errors at the plan 
level were estimated. Results: Overall RA biologic use was 17% in the sample (10 
% Part B and 7% Part D biologics). Compared to full-LIS patients, non-LIS patients 
had lower odds of initiating any RA biologic in the year (OR 0.84, 95% CI 0.75-0.94). 
Among biologic users, non-LIS patients were less likely to use a Part D biologic in 
the entire year (OR 0.19, 95% CI 0.15-0.24) and in the ICL-phase (OR 0.22, 95% CI 
0.17-0.28). cOnclusiOns: High cost sharing due to specialty tiers and the coverage 
gap under Part D may be associated with non-LIS patients foregoing use of any RA 
biologic or substituting with infusible biologics under Part B.
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Objectives: Real-world treatment behavior data among patients with Dupuytren’s 
contracture (DC) with a palpable cord are limited. The objective of this study was to 
assess real-world treatment behavior following Xiaflex®(collagenase clostridium 
histolyticum) or fasciectomy among adult DC patients. MethOds: A retrospec-
tive cohort analysis was conducted using the IMS LifeLink™ Health Plan Claims 
Database. Patients ≥ 18 years between 2/1/2010–12/31/2011, with a treated finger/
joint with Xiaflex or fasciectomy (index event), who were continuously enrolled 
both in the 12-month pre- and post-index periods, and had ≥ 1 DC diagnosis code 
in the pre-index period were included. A second treatment was defined as having 
occurred following a gap of ≥ 30 days from the index event. Descriptive statistics 
were reported and logistic regression and Cox Proportional Hazards models were 
used to adjust for baseline differences. Results: 309 Xiaflex/1,264 fasciectomy 
patients were included. Xiaflex patients were significantly older than fasciec-
tomy patients (64.28 vs. 61.50 years; p< 0.0001). Majority of all patients were male. 
Fasciectomy cohort had a greater proportion of patients with a second treatment 
than Xiaflex cohort (54% vs. 14%; p> 0.05). Nearly all patients received Xiaflex as 
their second treatment (99.12% vs.100% respectively). Demographic and clinical 
characteristics of patients receiving a second treatment among both cohorts were 
similar to those who did not receive a second treatment. After adjusting for baseline 
confounders, fasciectomy patients were 8.3-times more likely to have a second 
treatment compared to Xiaflex patients (OR: 8.28; 95% CI: 5.79-11.85; p< 0.0001). 
Older patients, patients with hyperlipidemia, hypothyroidsm, higher Charlson 
Comorbidity Index scores, and higher pre-index health care costs had a greater 
hazard of having a second treatment (all comparisons p< 0.05). cOnclusiOns: 
Xiaflex was used as a second treatment among nearly all DC patients. As such, 
fasciectomy patients may be candidates to be replaced by Xiaflex to reduce the risk 
and costs of a second treatment.
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Objectives: Various medications are commonly used to manage Rheumatoid 
Arthritis (RA). This study examined drug utilization patterns and factors associ-
ated with the use of medications by RA patients. MethOds: Data from the 2006-
2010 National Ambulatory Care Survey (NAMCS) and the outpatient department 
component of the National Hospital Ambulatory Medical Care Survey (NHAMCS) 
were used to examine the RA related ambulatory visits. RA medications were 
classified as NSAIDS and analgesics, corticosteroids, and disease modifying Anti-
rheumatic drugs (DMARDs). Bivariate chi-square analysis and multiple logistic 
regression analysis were performed to evaluate the factors associated with pre-
scribing of RA medications. SAS survey procedures that adjust for the complex 
sampling procedure of national surveys were used to conduct bivariate and 
multivariate analyses. Results: An average of 3.57 million (0.33%) visits was 
made by patients with RA from 2006 to 2010. Majority of these visits were 
made by females (76.75%), Whites (88.50%) and individuals aged 18-64 years old 
(61.53%). More than two third of the RA patients were prescribed anti-rheumatic 
Benefits associated with early detection and treatment of RA with biologics warrant 
closer scrutiny to alleviate patient burden.
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exPloring the differenCeS of diSeaSe, health StatUSeS and health 
Utilization BetWeen elderly With and WithoUt Bone diSorderS in 
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Objectives: Given the evidence showed that bone disorders were one of the top 
three prevalent chronic conditions among the elderly in Taiwan, the aim of this 
study was to explore the different characteristic, health status, health care utiliza-
tion between those who suffered from bone disorders or not among the elderly 
in Taiwan. MethOds: The data used for this study was obtained from the 2005 
National Health Interview Survey (NHIS) databases in Taiwan. The interviewees who 
reported to have “osteoporosis” or “osteoarthritis” were grouped into bone disorder 
group. Otherwise were non-bone disorder group. The appropriate descriptive sta-
tistics with sampling weights and inferential analysis approaches were applied on 
those responses for basic demographics, perceived health status, and self- report 
health care utilization. Results: Of 2727 elderly interviewees in 2005 NHIS, 35.2% 
reported to have bone disorders and their demographic characteristics were not 
statistically significant different from the other group, except the proportion of 
female. (65.0% vs 43%). While bone disorder group tended to have more chronic 
conditions than non-bone disorder group, they were also more likely to report fall 
experiences and worse health status Further, they tended to consume more utiliza-
tion of emergency care, hospital stay , dental care and Traditional Chinese medicine 
(TCM) service in past one year (all pvalues < 0.05) than otherwise. cOnclusiOns: 
Elderly with and without bone disorders in Taiwan were different not only in the 
demographic characteristics but also in their diseases, health status and health 
care utilization, including TCM service. Further comprehensive analyses would be 
needed to explore the extent of contributing factors on the health care utilization 
among elderly patients suffered from bone disorders.
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Brazilian Ministry of Health, Brasília, Brazil
Objectives: Until 2012, only the biological agents adalimumab, etanercept and 
infliximab were available in the Brazilian public health system (SUS) to treat 
Rheumatoid Arthritis (RA). Since July 2013, abatacept, certolizumab, golimumab, 
rituximab and tocilizumab were also made available, according to the treatment 
algorithm presented in the Brazilian Guidelines. The aim of this study is analyze 
the budget impact of these new technologies, by the MoH perspective. MethOds: 
The number of patients with RA treated with the new biologicals in the SUS was 
estimated by the ratio between the amount dispensed in 2013 and its recommended 
dosage. The data about the older biological agents were extracted from the SUS 
database (Datasus). The drug acquisition costs were used to calculate the rela-
tive treatment cost among the different therapeutic alternatives (current values; 
exchange rate: US$ 1 = R$ 2.36). The budget impact was calculated by comparing the 
new biologic treatment costs (abatacept, certolizumab, golimumab, rituximab and 
tocilizumab) and a potential costs in a hypothetical scenario without new agents 
available (only considering adalimumab, etanercept and infliximab). Results: From 
July to December 2013, 3,959 patients with RA were treated with new biologicals, 
implying a total spent of US$ 18,905,770.06. The mean monthly cost of treatment per 
patient was US$ 759.91, with higher values for abatacept (US$ 1,290.56) and lower 
for rituximab (US$ 579.10). If all of these patients were treated with the older agents, 
the total costs would sum up to US$ 41,497,979.83. Thus, the offer of new drugs in 
the SUS has saved a total of US$ 25,592,209.32 (54.44%) in 2013. cOnclusiOns: 
Offering new biologicals for RA allowed the SUS to expand the access to medicines 
and treatment of patients refractory to anti-TNF, also resulting potential savings 
for the SUS resources.
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BioSiMilarS: friendS or foe for PayerS, PhySiCianS and 
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White R.1, Mallinson M.2
1The Access Partnership, London, UK, 2Access Partnership, London, UK
Objectives: Following the recent approval of infliximab in the EU, the objectives 
were to understand EU payer and physicians expectations of the new biosimilars. 
How could biosimilars influence payer and physician decision-making and what 
must manufacturers do to achieve success? MethOds: Secondary research to 
understand payer drivers & local decision-making processes followed by 1:1stake-
holder interviews with 12 EU physicians on decision-making committee’s and 6 
EU Senior payers. Results: Awareness of biosimilars amongst physicians is cur-
rently low. Just 8% of physicians questioned in the EU spontaneously mentioned 
biosimilars as products in development, with Remsima/Inflectra the only biosimi-
lar mentioned specifically by name. Only 35% of the physicians said they would 
definitely consider prescribing biosimilars for Rheumatoid Arthritis within one 
year of launch. Payers are anticipating a 30% saving verses the originator drug. 
Payers warned that manufacturers need to treat biosimilars as if they were branded 
medicines, and ensure a proper commercial strategy. cOnclusiOns: The recent 
approval of Hospira’s Inflectra (infliximab) may mark a turning point for biosimilars 
in Europe. While follow-on biologics have been on the EU market since 2006, Inflectra 
was the first such approval for a monoclonal antibody – larger, more complex mol-
ecules than the 14 biosimilars previously cleared by the EMA. The broader context 
is that the exhaustion of patent and other intellectual-property rights on originator 
biologicals over the next decade affords an unparalleled opportunity for biosimilars 
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What faCtorS are aSSoCiated With inCreaSing ChargeS for Major 
joint rePlaCeMentS BetWeen 2008 and 2011?
Chiu G.R, Dong X., Wang Z., Meckley L.M., Miyasato G.
Trinity Partners, LLC, Waltham, MA, USA
Objectives: This study measured the association between hospital characteristics 
and changes in hospital charges for major joint replacement (MJR). MethOds: 
2008 and 2011 hospital charge and reimbursement data were obtained from MJR 
inpatient Medicare claims. Multivariate linear regression models were used at the 
hospital level to regress the percent change in hospital charges on hospital charac-
teristics which included hospital demographics and MJR patient summary meas-
ures. Independent variables represented both baseline 2008 and change in value/
status quantities. Results: The analysis included 3,016 hospitals. In multivariate 
models, many hospital characteristics were significantly associated with the per-
cent change in charges. Hospital type and census region were significantly related 
to percent change in charges. Specifically, Government and Non-Profit hospitals 
experienced smaller charge increases than Proprietary hospitals (-5.5% and -4.5% 
respectively, p< 0.0001). Compared to the Northeast, the West, South, and Midwest 
experienced 5.5%, 4.4%, and 3.3% increases in charges on average (p≤ 0.001), while 
the Midwest, West, and South were not statistically significantly different from each 
other (p> 0.05). Also, a one-day increase in the average length of stay was associ-
ated with an average charge increase of 6.7% (p< 0.0001). Overall, the final model 
accounted for 9% of the total variance. cOnclusiOns: Hospital characteristics, 
such as the region and type, as well as changes to average length of stay between 
2008 and 2011 were strong predictors of percent change in average charge for MJR. 
While several other factors were also statistically significantly related to change 
in charges for MJR, small effect sizes were not practically meaningful. The small 
percent of variance explained by the model leads us to conclude there are other 
factors not captured by Medicare data that are additionally responsible for growth 
in health care costs.
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Objectives: To evaluate health care costs and medication use patterns (persistence, 
discontinuation and switching) in patients with rheumatoid arthritis (RA) on etaner-
cept (ETN), infliximab (IFX) or adalimumab (ADA) in Texas Medicaid. MethOds: 
Prescription and medical claims for Texas Medicaid beneficiaries (18-63 years) 
with an RA diagnosis (ICD-9-CM code 714.0x) without claims for a biologic agent 
in the 6-months pre-index (July 1, 2003 to December 31, 2010) were analyzed over 
an 18-month study period between July 1, 2003 and August 31, 2011 (6-month 
pre- and 12-month post-index) based on their index biologic (ADA, ETN, or INF). 
The primary outcomes were 1-year persistence, discontinuation, switching and 
health care costs (RA-related and TNF inhibitor costs) to Texas Medicaid post-index, 
adjusted to 2011 US dollars using the medical consumer price index. Cohorts were 
constructed using propensity score (PS) matching controlling for baseline differ-
ences in demographics and clinical characteristics. Results: After PS matching, 
822 patients (n= 274/biologic group) comprised the final sample. The mean age (±SD) 
was 48.9 (±9.8) years, and the majority (69.2%) were between age 45 and 63, Hispanic 
(53.7%) and female (88.0%). Post-index mean (±SD) total health care costs were 
$16,477 (±$9,228), RA-related costs were $13,713 (±$8,309) and TNF inhibitor costs 
were $12,195 (±$8,517). For each cost variable (total health care, RA-related and TNF 
inhibitor costs), costs incurred by patients on ETN were significantly lower (p< 0.01) 
than those incurred by ADA patients but significantly higher (p< 0.01) than those 
incurred by IFX patients. Persistence to index TNF inhibitor therapy and likelihood 
to switch or discontinue were comparable among groups. Duration of medication 
use (i.e. persistence) prior to switching or discontinuation of index therapy was also 
comparable among groups. cOnclusiOns: The data suggest comparable medica-
tion use patterns but significantly different health care utilization costs among 
Texas Medicaid RA patients on ETN, IFX or ADA.
PMS83
Utilizing nordiC regiStrieS to SUPPort health eConoMiCS reSearCh 
in rheUMatiC diSeaSeS
Miller H.
Karolinska Institutet, Stockholm, Sweden
Objectives: Rheumatic diseases are often characterized by pain and disability. 
Many pharmaceuticals are available for their treatment and a considerable number 
of health economic(HE) studies have been published. Nordic countries maintain 
long-term comprehensive disease and drug registries. HE analyses, particularly 
those which are based on registry-data, can provide important information for 
health care decision makers. The primary objective of this study is to systematically 
review HE analyses of rheumatic diseases which utilize Nordic registry-data, and 
to provide a descriptive and critical analysis of this strategy. MethOds: Published 
literature was identified by searching the following databases: MEDLINE; EMBASE; 
Cochrane Library and Health Economic Evaluations Database; and PubMed. Search 
terms were pertinent to rheumatic diseases and HE. One reviewer screened and 
subsequently extracted data from studies which fulfilled inclusion/exclusion cri-
teria. References and citation search was done on included studies. Results: 45 
HE studies utilized Nordic registry-data. Studies were relevant to Sweden(n= 26), 
Norway(n= 11), Finland(n= 4) and Denmark(n= 4). Study types were modeling(n= 13), 
costing(n= 8), work/productivity(n= 6), quality-of-life(n= 13), and a combination 
of HE outcomes(n= 5). Registry data was used within the studies to characterize 
patients in regards to clinical(n= 29), demographic(n= 20), utility(n= 18) and cost/
drugs (70.75%). The most commonly prescribed anti-rheumatic drugs were NSAIDs 
and Analgesics (75.60%), DMARDs (20.40%) and Corticosteroids (4.00%). Multiple 
logistic regression analysis showed that females (OR: 0.55; 95% CI: 0.32-0.95), indi-
viduals aged group 18 to 64 years (OR: 0.48; 95% CI: 0.29-0.78) were less likely to 
receive anti-rheumatic drugs, whereas those seeking care from rheumatologists 
(OR: 4.38; 95% CI: 2.19-8.77) and those with multiple previous visits (OR: 1.43; 95% 
CI: 1.26-1.62) were more likely to receive anti rheumatic drugs. cOnclusiOns: 
Most (7 out of 10) visits for the RA involved use of anti-rheumatic drugs. Drug use 
patterns varied across age, gender, physician specialty, and previous use of health 
care. Further research is needed to evaluate the variation across drug classes 
for RA.
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relationShiP BetWeen the dUration of rheUMatology PraCtiCe 
exPerienCe and likelihood of USe and PerCePtion toWardS 
BioSiMilarS in rheUMatoid arthritiS (ra) arena
Narayanan S.
Ipsos Healthcare, Columbia, MD, USA
Objectives: To assess the relationship between duration of rheumatology practice 
experience and rheumatologist perception towards biosimilars and the likelihood of 
use of biosimilars to manage RA patients in the European Union (EU), Brazil, Japan 
and China. MethOds: A multi-country cross-sectional survey was conducted in 
top-5 EU countries (UK/Germany/Spain/France/Italy), Brazil, Japan and China in 
April/May 2013 using an online physician panel in the respective geographies; rheu-
matologists were randomly selected for survey participation to be geographically 
representative in select countries/regions. Surveys assessed the rheumatologist 
perceptions of biosimilars in terms of factors that would prevent them from using 
biosimilars among their biologic-eligible RA patients, and their likelihood of use of 
biosimilars. Summary statistics are reported across the markets, stratified by years 
of rheumatology-practice-experience. Results: 173 rheumatologists participated 
in the survey (5EU-58%, Brazil-23%, Japan-11% and China-9%); years of experience 
practicing rheumatology (across the markets) was: < = 10yrs:26%, 11-20yrs:42%, 
> 20yrs:32%. Mean RA patient-volume/year based on rheumatology-practice-expe-
rience was: < = 10yrs:264, 11-20yrs:323, > 20yrs:270. Likelihood of prescribing a bio-
similar product to eligible RA patients differed by rheumatology-practice-experience 
(< = 10yrs/11-20yrs/> 20yrs): definitely-13%/13%/5%; highly likely-27%/42%/39%; may 
be/not sure-44%/36%/38%; less/not likely-16%/10%/18%. Perceived duration of use of 
biosimilars in a small group of patients before prescribing it in larger scale was (by 
rheumatology-practice-experience < = 10yrs/11-20yrs/> 20yrs): 1-2yrs:53%/56%/43%, 
3-5yrs:16%/11%/14%, 6-10yrs:2%/1%/2%, > 10yrs:4%/4%/5%; not-sure:24%/28%/36%. 
Key factors noted by rheumatologists that would prevent them from using bio-
similars were (by rheumatology-practice-experience < = 10yrs/11-20yrs/> 20yrs): 
Doubts in similarity to original molecule(56%/63%/59%), inadequate safety/effi-
cacy profile/data(47%/57%/52%), lack of long-term data(42%/39%/57%), lack of 
national guidelines recommending the use of biosimilars(40%/38%/34%), lack of 
data from local country/market(40%/31%/25%), lack of trust/confidence in manu-
facturer(24%/25%/27%). cOnclusiOns: Rheumatologists perceptions varied based 
on their practice-experience; those with < = 10yrs of practice-experience reported 
the least likelihood of prescribing biosimilars, and a higher proportion of them cited 
national treatment guidelines and lack of data from local country/market among 
key reasons preventing biosimilar use.
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rheUMatoid arthritiS (ra) reCeiving a BiologiC MonotheraPy and 
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Objectives: To assess the clinical characteristics of patients with RA who received 
a biologic monotherapy (Mono) and biologic combination therapy (Combo: 
Biologic+DMARDs) in the US. MethOds: A multi-country multi-center medical 
chart-review study of RA patients was conducted between Nov2012-Jan2013 among 
physicians (mainly rheumatologists) in hospitals and private practices to collect 
de-identified data on patients who were recently treated with a biologic as part of 
usual care. Physicians were screened for duration of practice (3-30 yrs) and patient 
volume (incl. > 2RA biologic patients/week) and recruited from a large panel to be 
geographically representative of the US. Eligible patient charts (> 5) were randomly 
selected from a sample of prospective patients visiting each center/practice dur-
ing the screening period. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status. This analysis focused 
on patients currently on Mono and Combo biologics. Results: 919 eligible RA 
patients were included in the analysis; Mono patients: 353 (38%), Combo patients: 
566 (62%). Patient characteristics included (Mono/Combo): mean age:47.4/57.8; 
female:50%/61%; mean weight(Kg):75.7/78.0; top-3 comorbidities: obesity(17%/20%), 
dyslipidemia(14%/22%, depression/anxiety:9%/16%. Time between RA diagnosis 
and recent office visit (Mono/Combo):77.1/78.5months; number of biologic-lines 
of therapy received (Mono/Combo): 1st-line-80%/70%, 2nd-line-15%/20%, > = 3rd-
line-5%/11%; top-4 biologics used across the two patient groups were: adalimumab/
etanercept/infliximab/abatacept. Among patients with data-availability, current lab 
& disease-severity measures were (Mono/Combo): ESR(mm/h)-23.7/25.0; CRP(mg/
dl)-2.6/3.4; rheumatoid factor (positive%):38%/54%; anti-CCP (positive%):31%/45%; 
overall disease-stage per physician-judgment: mild-67%/62%, moderate-29%/33%, 
severe-4%/5%; mean-HAQ:0.7/0/9; mean-DAS28:2.3/3.0; mean tender joint count: 
2/3/3.4; mean swollen joint count:1.4/2.5. cOnclusiOns: In this cohort of RA 
patients in the US, over 60% of Mono and Combo patients had mild disease per 
physician judgment and a majority of them were on 1st line treatment; lab meas-
ures and joint counts indicated only slightly higher disease burden among Combo 
patients. Impact of specific biologic treatments on observed patterns and the need 
for therapeutic sequencing may warrant scrutiny.
